Overview

A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Status:
Active, not recruiting

Trial end date:
2021-08-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of ACH-0144471 in participants with paroxysmal nocturnal hemoglobinuria (PNH) who have demonstrated clinical benefit from ACH-0144471 in Study ACH471-100. This study is designed to include up to 12 participants.

Phase:

Phase 2

Details

Lead Sponsor:

Achillion Pharmaceuticals
Alexion Pharmaceuticals

Collaborator:

Achillion, a wholly owned subsidiary of Alexion